1-7 of 7
Elicia Penuel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Alex F. Herrera, Manish R. Patel, John M. Burke, Ranjana Advani, Bruce D. Cheson, Jeff P. Sharman, Elicia Penuel, Andrew G. Polson, Chen Di Liao, Chunze Li, Eva Schuth, Anjali Vaze, Divya Samineni, Rebecca Elstrom, James Cooper, Catherine Diefenbach
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1294–1301.
https://doi.org/10.1158/1078-0432.CCR-21-3261
Published: 01 April 2022
View article titled, Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study
Open the PDF for Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study in another window
Includes: Supplementary data
Journal Articles

A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer

Robert Piskol, Ling Huw, Ismail Sergin, Christiaan Kljin, Zora Modrusan, Doris Kim, Noelyn Kljavin, Rachel Tam, Rajesh Patel, Jeremy Burton, Elicia Penuel, Xueping Qu, Hartmut Koeppen, Teiko Sumiyoshi, Frederic de Sauvage, Mark R. Lackner, Felipe de Sousa e Melo, Omar Kabbarah
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4431–4442.
https://doi.org/10.1158/1078-0432.CCR-18-3032
Published: 15 July 2019
View article titled, A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer
Open the PDF for A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer in another window
Includes: Supplementary data
Journal Articles

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Dejan Juric, Rodrigo Dienstmann, Andres Cervantes, Manuel Hidalgo, Wells Messersmith, George R. Blumenschein, Jr, Josep Tabernero, Desamparados Roda, Antonio Calles, Antonio Jimeno, Xiaodong Wang, Sandra Sanabria Bohórquez, Cecilia Leddy, Catherine Littman, Amy V. Kapp, David S. Shames, Elicia Penuel, Lukas C. Amler, Andrea Pirzkall, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (11): 2462–2470.
https://doi.org/10.1158/1078-0432.CCR-14-2412
Published: 31 May 2015
View article titled, Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
Open the PDF for Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors in another window
Journal Articles

MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

Xiangnan Du, Benjamin C. Lin, Qian-Rena Wang, Hao Li, Ellen Ingalla, Janet Tien, Isabelle Rooney, Avi Ashkenazi, Elicia Penuel, Jing Qing
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (24): 6324–6335.
https://doi.org/10.1158/1078-0432.CCR-13-3336
Published: 14 December 2014
View article titled, MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Open the PDF for MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Hartmut Koeppen, Wei Yu, Jiping Zha, Ajay Pandita, Elicia Penuel, Linda Rangell, Rajiv Raja, Sankar Mohan, Rajesh Patel, Rupal Desai, Ling Fu, An Do, Vaishali Parab, Xiaoling Xia, Tom Januario, Sharianne G. Louie, Ellen Filvaroff, David S. Shames, Ignacio Wistuba, Marina Lipkind, Jenny Huang, Mirella Lazarov, Vanitha Ramakrishnan, Lukas Amler, See-Chun Phan, Premal Patel, Amy Peterson, Robert L. Yauch
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4488–4498.
https://doi.org/10.1158/1078-0432.CCR-13-1836
Published: 01 September 2014
View article titled, Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
Open the PDF for Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit in another window
Includes: Supplementary data
Journal Articles

Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Antoni Ribas, Jiang Li, Hartmut Koeppen, Mark Merchant, Richard Neve, Jeff Settleman, Yibing Yan, Elicia Penuel, Luciana Burton, Emily Chan, Jing Peng, Eva Lin, Yulei Wang, Jeff Sosman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): PR6.
https://doi.org/10.1158/1078-0432.MECHRES-PR6
Published: 04 March 2013
View article titled, Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors
Open the PDF for Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors in another window
Journal Articles

Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

Jeff Sperinde, Xueguang Jin, Jayee Banerjee, Elicia Penuel, Anasuya Saha, Gundo Diedrich, Weidong Huang, Kim Leitzel, Jodi Weidler, Suhail M. Ali, Eva-Maria Fuchs, Christian F. Singer, Wolfgang J. Köstler, Michael Bates, Gordon Parry, John Winslow, Allan Lipton
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (16): 4226–4235.
https://doi.org/10.1158/1078-0432.CCR-10-0410
Published: 11 August 2010
View article titled, Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
Open the PDF for Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients in another window
Includes: Supplementary data